FDA Requests New Trial for Aldeyra Therapeutics’ Dry Eye Disease Drug

Aldeyra Therapeutics on Monday announced receipt of an FDA complete response letter (CRL) for the NDA of reproxalap, for the treatment of dry eye disease, asking the company to conduct an additional trial to show the efficacy of the drug.
Source: Drug Industry Daily